Menu

DigitalHealth

WhiteHat Jr Founder Secures $16M for US Cancer Care Venture, Complement1

WhiteHat Jr Founder Secures $16M for US Cancer Care Venture, Complement1

WhiteHat Jr Founder Secures $16M for US Cancer Care Venture, Complement1

 

From coding education to cancer care, Karan Bajaj’s new venture aims to transform oncology outcomes through tech-enabled, personalized lifestyle coaching.

A New Chapter: From Edtech to Healthtech

Karan Bajaj, renowned for founding WhiteHat Jr-a platform that taught coding to children and was acquired by BYJU’S for $300 million in 2020-has shifted his entrepreneurial focus from education to healthcare. His latest venture, Complement1, is based in the United States and targets a critical gap in cancer care: the integration of evidence-based lifestyle interventions into the treatment and recovery process.
After his exit from BYJU’S in 2021 and a period of personal reflection, Bajaj returned to the startup scene with a mission to address the unmet needs of cancer patients, survivors, and those at high risk. Complement1 combines advanced technology, evidence-based clinical practices, and personalized coaching to deliver impactful and enduring benefits for patients.

Complement1: The Vision and Model
Personalized, Daily Support:
Complement1 offers individualized daily support to cancer patients and those at high risk through personalized sessions led by dedicated CoActive Coaches.
These coaches help users incorporate clinically recommended practices in nutrition, physical activity, sleep, and stress management-areas often overlooked in conventional cancer care.

Tech-Enabled, Clinically Validated:

The platform leverages an AI-driven personalization engine to tailor interventions and education for each user. Complement1’s approach is backed by clinical studies, showing outcomes such as a 37% reduction in treatment-related side effects, an 18% decrease in pain levels, and a 27% improvement in sleep quality for its members.
The program boasts over 90% adherence rates, a testament to its daily engagement strategy.
Integration with Healthcare Ecosystem:
Complement1 partners with cancer centers, health plans, and employers to make its platform available to a wider population. Early actuarial modeling suggests that its approach can reduce healthcare costs for cancer patients by up to 30%, benefiting not just individuals but also providers and insurers.

Funding and Growth Plans

Complement1 has secured $16 million in seed funding, led by Owl Ventures and Blume Ventures, along with support from unnamed investors. The funding will be directed toward:
• Expanding the company’s coaching capabilities and operational presence across the U.S.
• Developing its AI-powered personalization platform further
• Improving the digital interface for both users and coaching staff
• Building strategic collaborations with hospitals, insurance providers, and corporate partners
Amit A. Patel, Managing Director at Owl Ventures, commended Complement1 for its unique blend of advanced technology and personalized coaching, calling it a “game-changing approach to transforming cancer care outcomes worldwide.”

The Rise of Second-Time Founders

Bajaj’s journey reflects a growing trend in the Indian and global startup ecosystem, successful founders returning with new, often more ambitious ventures. After high-profile exits, many leaders are leveraging their experience and networks to tackle complex problems in sectors like healthtech, fintech, and sustainability. Bajaj’s shift from edtech to healthtech reflects a broader trend of adaptability and evolving vision among seasoned entrepreneurs.

Lessons from WhiteHat Jr

WhiteHat Jr’s meteoric rise and subsequent controversies-including aggressive marketing, regulatory scrutiny, and eventual shutdown-have shaped Bajaj’s approach to Complement1. This time, the emphasis is on clinical validation, compassionate engagement, and measurable impact. The startup’s initial outcomes and backing from investors indicate a promising base for long-term, scalable expansion.

Conclusion

Karan Bajaj’s Complement1 is poised to make a significant impact on cancer care by addressing the critical, yet often neglected, role of lifestyle interventions in treatment and recovery. With robust funding, a clinically validated approach, and a focus on personalized, tech-enabled coaching, Complement1 is set to redefine support for cancer patients and high-risk individuals. The venture not only marks Bajaj’s successful transition from edtech to healthtech but also signals a broader shift towards holistic, patient-centered care in the digital age.

 

 

 

 

 

 

The image added is for representation purposes only

BEL Sees Stock Rally After Akashteer Demonstration

 

Star Health Q4 FY25: Profits Drop, Claims Surge!

Star Health Q4 FY25: Profits Drop, Claims Surge!

Star Health Q4 FY25: Profits Drop, Claims Surge!

 

Despite robust double-digit growth in gross written premiums and a broader rural footprint, Star Health’s Q4 performance highlights rising claims expenses and a dramatic total collapse in net profit.

Summary:

Star Health and Allied Insurance reported a sharp decline in profits for Q4 FY25, recording an underwriting loss of ₹378 crore. The company’s combined ratio increased to 101.1%, climbing from 97.3% in the prior year, signaling a worrisome shift. Although the insurer saw a 10% YoY increase in Gross Written Premium and robust digital expansion, higher medical inflation and claim payouts led to significant financial strain.

A Disappointing Quarter for Star Health

Star Health and Allied Insurance Company Ltd. has reported a dramatic decline in its profitability for the fourth quarter and full year ended March 31, 2025. The standalone net profit plummeted by almost 100%, with the insurer posting an underwriting loss of ₹378 crore in FY25, compared to a modest ₹89 crore profit in FY24.
Profit after tax (PAT) fell to ₹646 crore under IGAAP and ₹787 crore under IFRS, down from ₹845 crore and ₹1,103 crore, respectively, in the previous year. The decline was caused by a rise in claims, healthcare cost inflation, and an increase in the combined ratio to 101.1%, surpassing the critical 100% mark. This suggests that the company’s claim payouts and operational costs exceed the revenue generated from premium collections.

Claims Surge and Expense Pressure

During FY25, the company paid over ₹10,350 crore in claims, a significant rise from previous years. Speciality categories such as orthopaedics, cardiology, cancer, and infectious diseases consumed close to ₹1,000 crores in payouts, with ₹2,000 crores paid out to senior citizens alone. The net incurred claim ratio rose to 70.3% under IGAAP and 70.7% under IFRS, indicating a surge in claim volumes beyond projections.
Operating expenses remained elevated at 30.4%, with administrative and distribution costs remaining high despite technology-led efficiency initiatives.

GWP Growth Strong, but Profitability Concerns Mount

Even though the bottom-line figures were disappointing, the company reported consistent growth in its top-line metrics. Gross Written Premium (GWP) rose 10% YoY to ₹16,781 crore under the new 1/n accounting norm and 15% to ₹17,553 crore without the 1/n adjustment. Retail health, contributing 93% of total GWP, remained the company’s core growth engine.
Renewal premium retention also stayed healthy at 97%, reflecting continued trust from existing policyholders.

Digital and Rural Expansion Pay Off

A highlight for the quarter was the company’s continued investment in digital and rural outreach. Star Health’s digital platform saw a 71% increase in fresh business through digital channels, 89% of policies were sourced digitally, and over 63% of renewals were done without human intervention.
Moreover, 51% of all insured people who lived during FY25 came from semi-urban and rural India. Notably, 60% of the retail claims settled were from these non-metro areas, aligning with Star Health’s aim of inclusive coverage.

Solvency and Investment Performance Remain Stable

The company demonstrated robust financial health with a solvency ratio 2.21x, well above the IRDAI requirement of 1.5x. This highlights a strong ability to meet sustained obligations over time. Additionally, total investment assets impressively reached ₹17,898 crore, reflecting a solid investment strategy. Furthermore, the investment yield experienced a marginal increase, rising to 7.8% from 7.7% in the previous fiscal year (FY24), highlighting the effectiveness of the company’s investment operations.

Management Commentary and Outlook

In a recent statement, Managing Director and CEO Anand Roy emphasized Star Health’s unwavering commitment to broadening its retail business, particularly in historically underserved regions. He outlined a range of forthcoming initiatives to promote customer-focused care models, innovative wellness programs, and accessible home healthcare services designed to enhance patient experiences.

Roy acknowledged the persistent challenges posed by rising inflation in healthcare costs, creating a more complicated landscape for service delivery. Nevertheless, he expressed confidence that the path forward lies in leveraging technology to drive efficiency and implementing prudent risk management strategies to navigate these economic pressures effectively. His insights paint a picture of a forward-thinking organization dedicated to adapting and thriving in a changing healthcare environment.

Conclusion: A Tough Quarter, But Not Without Silver Linings

Star Health’s Q4 and full-year FY25 performance presents a classic case of substantial growth marred by cost escalation and margin erosion. While the company’s leadership in retail health and strong solvency offer stability, sustained profitability will depend on effective underwriting, prudent pricing, and sharper cost controls. The year ahead is likely crucial as the company works to return to a healthier profit trajectory.

 

 

 

 

The image added is for representation purposes only

In India, Bosch Launches a Smart Supply Chain Platform